Singer Capital Markets strengthens Healthcare & Life Sciences franchise with two new hires

Singer Capital Markets is delighted to announce the appointment of two new hires into our Healthcare & Life Sciences research team.

We welcome Dr. Karl Keegan as a Senior Research Analyst who has over 25 years’ experience in the sector, both as a sell side equity analyst as well as in finance and business development. In addition, we welcome Dr. Kegan McColgan-Bannon who joins us as a Research Analyst, having previously worked on Medical Affairs and Commercial Strategy projects with large cap pharmaceutical clients.

Kegan will also collaborate closely with our Senior Healthcare Analyst, Chris Glasper, and collectively the team will be extending coverage across a broad spectrum of UK quoted companies in the Healthcare and Life Sciences space, supporting the firm’s active role in secondary market liquidity, access to primary capital and continual support to our quoted corporate clients.

We are pleased to welcome Karl & Kegan to the firm after a strong period of momentum for Singer Capital Markets, where we are now currently ranked joint first for total number of Healthcare clients on AIM.